文献速递头颈与中枢神经肿瘤

清醒开颅术在功能区胶质母细胞瘤中的效果(GLIOMAP):一项国际多中心队列研究的倾向评分匹配分析

Effect of awake craniotomy in glioblastoma in eloquent areas (GLIOMAP): a propensity score-matched analysis of an international, multicentre, cohort study.
PubMed 文献 · Lancet Oncol · 2022-05-12

这项国际多中心队列研究的倾向评分匹配分析纳入536例功能区原发性胶质母细胞瘤患者,比较清醒开颅与睡眠下切除。清醒开颅组在3个月和6个月术后神经功能缺损更少,总生存期和无进展生存期更长;亚组分析中,<70岁、NIHSS 0-1分和KPS 90-100分的患者获益一致,而≥70岁、NIHSS≥2分或KPS≤80分者生存无差异。

要点

  • 匹配队列中清醒开颅组3个月神经功能缺损22% vs 睡眠组33%(p=0.019),6个月26% vs 41%(p=0.0048)。
  • 清醒开颅组中位总生存17.0个月 vs 睡眠组14.0个月(p=0.00054),中位无进展生存9.0个月 vs 7.3个月(p=0.0060)。
  • 亚组中<70岁、NIHSS 0-1分、KPS 90-100分患者从清醒开颅中获益;≥70岁、NIHSS≥2分或KPS≤80分者生存无差异。

核心结论

  • 这些数据可能有助于神经外科医生评估个别胶质母细胞瘤患者的手术策略。
  • 这些发现将在SAFE试验(NCT03861299)和PROGRAM研究(NCT04708171)中得到验证和进一步探索。

研究设计与样本

  • 这是一项国际多中心队列研究(GLIOMAP)的倾向评分匹配分析,患者来自欧洲四家三级中心(荷兰鹿特丹Erasmus MC和Haaglanden MC、比利时鲁汶UZ Leuven)和美国波士顿Brigham and Women's Hospital。
  • 纳入标准为年龄18-90岁、接受切除术、组织病理学诊断为原发性胶质母细胞瘤、肿瘤位于功能区或近功能区、且有单灶强化病灶。
  • 患者根据治疗医生或多学科肿瘤委员会决定接受清醒开颅术中定位或睡眠下切除。
  • 采用1:3倾向评分匹配将清醒组与睡眠组匹配,并按年龄(<70岁 vs ≥70岁)、术前NIHSS评分(0-1分 vs ≥2分)和术前KPS(90-100 vs ≤80)分层进行亚组匹配。
  • 2010年1月1日至2020年10月31日共招募3919例患者,其中1047例接受原发性功能区胶质母细胞瘤肿瘤切除术并纳入未匹配总队列分析;倾向评分匹配后总匹配队列包含536例患者,其中134例接受清醒开颅术,402例接受睡眠下切除。

主要发现

  • 在总匹配队列中,清醒开颅组与睡眠下切除组相比,术后3个月神经功能缺损更少(26/120 [22%] vs 107/323 [33%];p=0.019),术后6个月也更少(30/115 [26%] vs 125/305 [41%];p=0.0048)。
  • 在总匹配队列中,清醒开颅组中位总生存期长于睡眠下切除组(17.0个月 [95% CI 15.0-24.0] vs 14.0个月 [13.0-16.0];p=0.00054),中位无进展生存期也更长(9.0个月 [8.0-11.0] vs 7.3个月 [6.0-8.8];p=0.0060)。
  • 在<70岁患者中,清醒开颅组与睡眠下切除组相比,3个月神经功能缺损更少(22/103 [21%] vs 93/272 [34%];p=0.016),6个月也更少(24/101 [24%] vs 108/258 [42%];p=0.0014)。
  • 在NIHSS评分0-1分患者中,清醒开颅组与睡眠下切除组相比,3个月神经功能缺损更少(22/96 [23%] vs 97/254 [38%];p=0.0071),6个月也更少(27/95 [28%] vs 115/239 [48%];p=0.0010)。
  • 在KPS 90-100分患者中,清醒开颅组与睡眠下切除组相比,3个月神经功能缺损更少(17/88 [19%] vs 74/237 [35%];p=0.034),6个月也更少(24/87 [28%] vs 101/223 [45%];p=0.0043)。

关键数值与推荐

  • 在≥70岁患者中,清醒开颅组与睡眠下切除组相比,3个月神经功能缺损更少(2/16 [13%] vs 15/35 [43%];p=0.033),6个月无差异。
  • 在NIHSS评分≥2分患者中,清醒开颅组与睡眠下切除组相比,3个月神经功能缺损更少(3/23 [13%] vs 21/58 [36%];p=0.040)。
  • 在KPS≤80分患者中,清醒开颅组与睡眠下切除组相比,6个月神经功能缺损更少(5/28 [18%] vs 34/88 [39%];p=0.043),3个月无差异。
  • 在<70岁患者中,清醒开颅组中位总生存期长于睡眠下切除组(19.5个月 [95% CI 16.0-31.0] vs 15.0个月 [13.0-17.0];p<0.0001),中位无进展生存期也更长(9.3个月 [8.0-12.0] vs 7.5个月 [6.5-9.0];p=0.0061)。
  • 在NIHSS评分0-1分患者中,清醒开颅组中位总生存期长于睡眠下切除组(18.0个月 [16.0-31.0] vs 14.0个月 [13.0-16.5];p=0.00047),中位无进展生存期也更长(9.5个月 [9.0-12.0] vs 8.0个月 [6.5-9.0];p=0.0035)。

临床怎么用

  • 作者认为这些数据可能有助于神经外科医生评估个别胶质母细胞瘤患者的手术策略。
  • 作者指出这些发现将在SAFE试验(NCT03861299)和PROGRAM研究(NCT04708171)中得到验证和进一步探索。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Awake mapping has been associated with decreased neurological deficits and increased extent of resection in eloquent glioma resections. However, its effect within clinically relevant glioblastoma subgroups remains poorly understood. We aimed to assess the benefit of this technique in subgroups of patients with glioblastomas based on age, preoperative neurological morbidity, and Karnofsky Performance Score (KPS). METHODS: In this propensity score-matched analysis of an international, multicentre, cohort study (GLIOMAP), patients were recruited at four tertiary centres in Europe (Erasmus MC, Rotterdam and Haaglanden MC, The Hague, Netherlands, and UZ Leuven, Leuven, Belgium) and the USA (Brigham and Women's Hospital, Boston, MA). Patients were eligible if they were aged 18-90 years, undergoing resection, had a histopathological diagnosis of primary glioblastoma, their tumour was in an eloquent or near-eloquent location, and they had a unifocal enhancing lesion. Patients either underwent awake mapping during craniotomy, or asleep resection, as per treating physician or multidisciplinary tumour board decision. We used propensity-score matching (1:3) to match patients in the awake group with those in the asleep group to create a matched cohort, and to match patients from subgroups stratified by age (<70 years vs ≥70 years), preoperative National Institute of Health Stroke Scale (NIHSS) score (score of 0-1 vs ≥2), and preoperative KPS (90-100 vs ≤80). We used Cox proportional hazard regressions to analyse the effect of awake mapping on the primary outcomes including postoperative neurological deficits (measured by deterioration in NIHSS score at 6 week, 3 months, and 6 months postoperatively), overall survival, and progression-free survival. We used logistic regression to analyse the predictive value of awake mapping and other perioperative factors on postoperative outcomes. FINDINGS: Between Jan 1, 2010, and Oct 31, 2020, 3919 patients were recruited, of whom 1047 with tumour resection for primary eloquent glioblastoma were included in analyses as the overall unmatched cohort. After propensity-score matching, the overall matched cohort comprised 536 patients, of whom 134 had awake craniotomies and 402 had asleep resection. In the overall matched cohort, awake craniotomy versus asleep resection resulted in fewer neurological deficits at 3 months (26 [22%] of 120 vs 107 [33%] of 323; p=0·019) and 6 months (30 [26%] of 115 vs 125 [41%] of 305; p=0·0048) postoperatively, longer overall survival (median 17·0 months [95% CI 15·0-24·0] vs 14·0 months [13·0-16·0]; p=0·00054), and longer progression-free survival (median 9·0 months [8·0-11·0] vs 7·3 months [6·0-8·8]; p=0·0060). In subgroup analyses, fewer postoperative neurological deficits occurred at 3 months and at 6 months with awake craniotomy versus asleep resection in patients younger than 70 years (3 months: 22 [21%] of 103 vs 93 [34%] of 272; p=0·016; 6 months: 24 [24%] of 101 vs 108 [42%] of 258; p=0·0014), those with an NIHSS score of 0-1 (3 months: 22 [23%] of 96 vs 97 [38%] of 254; p=0·0071; 6 months: 27 [28%] of 95 vs 115 [48%] of 239; p=0·0010), and those with a KPS of 90-100 (3 months: 17 [19%] of 88 vs 74 [35%] of 237; p=0·034; 6 months: 24 [28%] of 87 vs 101 [45%] of 223, p=0·0043). Additionally, fewer postoperative neurological deficits were seen in the awake group versus the asleep group at 3 months in patients aged 70 years and older (two [13%] of 16 vs 15 [43%] of 35; p=0·033; no difference seen at 6 months), with a NIHSS score of 2 or higher (3 months: three [13%] of 23 vs 21 [36%] of 58; p=0·040) and at 6 months in those with a KPS of 80 or lower (five [18%] of 28 vs 34 [39%] of 88; p=0·043; no difference seen at 3 months). Median overall survival was longer for the awake group than the asleep group in the subgroups younger than 70 years (19·5 months [95% CI 16·0-31·0] vs 15·0 months [13·0-17·0]; p<0·0001), an NIHSS score of 0-1 (18·0 months [16·0-31·0] vs 14·0 months [13·0-16·5]; p=0·00047), and KPS of 90-100 (19·0 months [16·0-31·0] vs 14·5 months [13·0-16·5]; p=0·00058). Median progression-free survival was also longer in the awake group than in the asleep group in patients younger than 70 years (9·3 months [95% CI 8·0-12·0] vs 7·5 months [6·5-9·0]; p=0·0061), in those with an NIHSS score of 0-1 (9·5 months [9·0-12·0] vs 8·0 months [6·5-9·0]; p=0·0035), and in those with a KPS of 90-100 (10·0 months [9·0-13·0] vs 8·0 months [7·0-9·0]; p=0·0010). No difference was seen in overall survival or progression-free survival between the awake group and the asleep group for those aged 70 years and older, with NIHSS scores of 2 or higher, or with a KPS of 80 or lower. INTERPRETATION: These data might aid neurosurgeons with the assessment of their surgical strategy in individual glioblastoma patients. These findings will be validated and further explored in the SAFE trial (NCT03861299) and the PROGRAM study (NCT04708171). FUNDING: None.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Gerritsen JKW, Zwarthoed RH, Kilgallon JL, et al. Effect of awake craniotomy in glioblastoma in eloquent areas (GLIOMAP): a propensity score-matched analysis of an international, multicentre, cohort study. Lancet Oncol. 2022. PMID: 35569489. doi:10.1016/S1470-2045(22)00213-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。